Mixed cellularity classical Hodgkin lymphoma (MCcHL)

2016-06-01   Annunziata Gloghini , Antonino Carbone 

1.Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC); Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; annunziata.gloghini@istitutotumori.mi.it (AG)
2.Department of Pathology Centro di Riferimento Oncologico Aviano (CRO), Istituto Nazionale Tumori, IRCCS, Aviano, Italy; acarbone@cro.it (AC); Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; annunziata.gloghini@istitutotumori.mi.it (AG)

Abstract

Over the past 50 years, a relevant progress has been made toward our understanding of classical Hodgkin lymphoma pathology and cell biology. Histologic classification evolved through different systems to the 2008 World Health Organization classification, upgraded in 2016.

Clinics and Pathology

Noted

Most patients affected by mixed cellularity (MC) classical Hodgkin lymphoma (cHL) present with B symptoms and in intermediate stages (II and III), compared with frequent stage II presentation in nodular sclerosis (NS) cHL. Peripheral lymph nodes are commonly involved. Splenic and liver involvement are frequent, whereas bone marrow and other organs involvement are less frequent.

Disease

Based on the characteristics of the Hodgkin and Reed-Sternberg (HRS) tumour cells (lacunar cells, multinucleated giant cells, pseudosarcomatous cells) and of the reactive infiltrate, four histologic subtypes of cHL have been distinguished: lymphocyte-rich cHL (LRCHL), nodular sclerosis (NS) cHL, mixed cellularity (MC) cHL, and lymphocyte depletion (LD) cHL. Most cHL can be classified as NS or MC subtypes.
MC is a subtype of cHL characterized by diagnostic HRS cells in a mixed inflammatory back-ground without sclerosis. Mononuclear Hodgkin cells can be present. The mixed cellular background is considered the hallmark of the MCcHL subtype. In particular, heterogeneous constituents including admixed eosinophils, plasma cells, histiocytes and small lymphocytes are usually found. The composition of this background varies greatly.

Phenotype stem cell origin

Cell origin
Like HRS cells of other cHL subtypes, the tumour cells of MCcHL derive from preapoptotic crippled Germinal Center (GC) B cells. They are derived from GC B cells that have acquired disadvantageous immunoglobulin variable chain gene mutations (Kuppers et al., 2012), have lost the expression of most B-cell genes and acquired expression of genes that are typical for other types of hematopoietic and lymphoid cells (Greaves and Gribben 2012; Steidl et al. 2012; Tiacci et al., 2012).
Phenotype
Phenotypically, tumour cells of MCcHL are CD30 and CD15 positive (Stein et al., 2008) and exhibit additional expression of the following markers:
- Plasma cell markers (MUM1/IRF4) usually positive.
- Molecules involved in Ag presentation (MHC class II, CD40, CD80, CD86) consistently positive.
Cellular components of the cHL microenvironment express molecules involved in cancer cell growth and survival (such as CD30L or CD40L), and in immune escape (programmed death 1 (PD-1). A fraction of infiltrating CD4+ T cells are regulatory T (Treg) cells. Treg cells and PD-1+ T cells also interact with HRS cells (Aldinucci et al., 2010; Liu et al., 2014; Carbone et al., 2015).

Epidemiology

Classical Hodgkin lymphoma is a distinct neoplastic entity with heterogeneous epidemiological features. It accounts for approximately 10% of all malignant lymphomas (Stein et al., 2008).Classical HL is the most common cancer in patients under 20 years (adolescents and younger adults). The first peak of incidence can be observed in patients under 35 years of age, whereas a second incidence peak can be observed in the elderly (Hjalgrim et al, 2008; Stein et al., 2008).
MCcHL accounts for approximately 20-25% of cHL. MCcHL is more frequent in patients with HIV infection and in resource poor areas. The incidence of MCcHL is more frequent in male than in females and peaks at age 35-40 years.
Atlas Image
Figure 1. A typical multinucleated Hodgkin Reed-Sternberg cell is seen at the center.

Cytology

The recognition of MCcHL is based on the presence of diagnostic HRS cells in a specific inflammatory background, the composition of which varies greatly and includes eosinophils, neutrophils, histiocytes and plasma cells. Binucleated and multinucleated HRS cells with bi- or multinucleation and huge nucleoli are pathognomonic for MCcHL identification.

Pathology

HRS cells reside in an inflammatory cell microenvironment. In MCcHL, like in other cHL subtypes, microenvironmental cell types include T- and B-reactive lymphocytes, eosinophils, granulocytes, histiocytes/macrophages, plasma cells, mast cells.
Atlas Image
Figure 2. The CD30 immunostaining highlights the presence of Hodgkin Reed-Sternberg cells and some mononucleated Hodgkin cells
Atlas Image
Figure 3. EBER and EBV-encoded LMP1 (inset) are expressed by multinucleated Reed-Sternberg cells as nuclear and cytoplasmic staining, respectively

Other features

Virology
EBV is found in HRS cells preferentially in cases of MC and LD cHL, and less frequently in NS and LRCHL. Notably, EBV is found in HRS cells in nearly all cases of cHL occurring in patients infected with HIV (IARC 2012; Younes et al., 2014; Dolcetti et al., 2016).
Table 1. Heterogeneity of classical Hodgkin lymphoma according to the morphologic and virologic characteristics.

 

Hodgkin  lymphoma  subtype

EBV infection

 

HL of the general population

 

 

 

 

Nodular lymphocyte predominance

Absent

 

 

cHL, nodular sclerosis

Usually absent *

 

 

cHL, mixed cellularity

Usually present *

 

 

Rare types

 

 

 

cHL, lymphocyte rich

Variably present

 

 

cHL, lymphocyte depleted

Variably present

 

 

 

 

 

HIV-associated HL

 

 

 

 

cHL, lymphocyte depleted

Present

 

 

cHL, mixed cellularity

Present

 

 

Less frequent

 

 

 

cHL, lymphohistiocyoid

Present

 

 

cHL, nodular sclerosis

Present

 

Post-transplant (cHL type PTLD)

 

 

 

 

Similar to other cHL

Present

 

Iatrogenic (methotrexate)

 

 

 

 

cHL, mixed cellularity

Variably present (usually present)

 

 

 

 

 


Abbreviations. cHL, classical Hodgkin lymphoma; PTLD, post-transplant lymphoproliferative disorder

*Association with EBV is less frequent in ns (10-40%) than in mc cHL (approximately 75% of cases).

Treatment

Like in other cHL subtypes, cure rates approaching 80% have been achieved in patients undergoing chemo-radiotherapy, qualifying cHL as a chemosensitive disease (Santoro et al., 1987, Canellos et al., 2014).

Prognosis

MCcHL exhibit a better prognosis than that of NScHL.

Note

Recurrent genetic alterations have been identified in HRS cells of cHL (including MCcHL). These lesions affecting members of the NF-kappaB or JAK/STAT signalling pathways (Küppers and Re, 2007; Hartmann et al., 2008; Steidl et al., 2010; Küppers 2011; Küppers et al., 2012; Pasqualucci and Dalla Favera, 2014).
See also the pertinent section within the CARDS describing the general features of cHL (Küppers, 2011; Carbone and Gloghini, 2016).

Bibliography

Pubmed IDLast YearTitleAuthors
205270192010The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.Aldinucci D et al
244415262014Treatment of Hodgkin lymphoma: a 50-year perspective.Canellos GP et al
259536222015Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Carbone A et al
267730452016A lymphomagenic role for HIV beyond immune suppression?Dolcetti R et al
231975792012Lymphoid neoplasia. Laser-capturing the essence of Hodgkin lymphoma.Greaves P et al
186410272008Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.Hartmann S et al
190171782008Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence.Hjalgrim H et al
230237152012Hodgkin lymphoma.Küppers R et al
238673032014The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component.Liu Y et al
193806392009TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.Schmitz R et al
214830012011Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment.Steidl C et al
229559182012Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.Steidl C et al
203390892010Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome.Steidl C et al
269807272016The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Swerdlow SH et al
229559142012Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.Tiacci E et al

Citation

Annunziata Gloghini ; Antonino Carbone

Mixed cellularity classical Hodgkin lymphoma (MCcHL)

Atlas Genet Cytogenet Oncol Haematol. 2016-06-01

Online version: http://atlasgeneticsoncology.org/haematological/1566/mixed-cellularity-classical-hodgkin-lymphoma-(mcchl)